A. Fourquet, ONCOPOOL -a European database for 16,944 cases of breast cancer, Eur J Cancer. janv, vol.46, issue.1, pp.56-71, 2010.

F. Penault-llorca, F. André, C. Sagan, M. Lacroix-triki, Y. Denoux et al., Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor???Positive Breast Cancer, Journal of Clinical Oncology, vol.27, issue.17, pp.2809-2815, 2009.
DOI : 10.1200/JCO.2008.18.2808

C. Early-breast, . Trialists-'collaborative, and . Group, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women, Lancet, vol.339, pp.71-85, 1992.

W. Han, S. Kim, I. Park, D. Kang, S. Kim et al., Young age: an independent risk factor for disease-free survival in women with operable breast cancer, BMC Cancer, vol.107, issue.1
DOI : 10.1002/ijc.11460

D. Morrison, D. Rahardja, E. King, Y. Peng, and V. Sarode, Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer, British Journal of Cancer, vol.16, issue.2, pp.382-387, 2012.
DOI : 10.1016/S1470-2045(09)70262-1

D. Allred, J. Harvey, M. Berardo, and G. Clark, Prognostic and predictive factors in breast cancer by immunohistochemical analysis, Mod Pathol. févr, vol.11, issue.2, pp.155-168, 1998.

V. Bardou, G. Arpino, R. Elledge, C. Osborne, and G. Clark, Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases, Journal of Clinical Oncology, vol.21, issue.10, pp.1973-1979, 2003.
DOI : 10.1200/JCO.2003.09.099

C. Elston and I. Ellis, pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, vol.9, issue.5
DOI : 10.1016/0277-5379(88)90171-X

D. Azambuja, E. Cardoso, F. De-castro, G. Jr, M. Colozza et al., Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12???155 patients, British Journal of Cancer, vol.27, issue.10, pp.1504-1513, 2007.
DOI : 10.1002/1097-0142(19910115)67:2<421::AID-CNCR2820670217>3.0.CO;2-Q

M. Aleskandarany, E. Rakha, and R. Macmillan, MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups, Breast Cancer Research and Treatment, vol.23, issue.7, pp.591-600, 2010.
DOI : 10.1007/s10549-010-1028-3

URL : https://hal.archives-ouvertes.fr/hal-00615364

M. Cheang, S. Chia, and D. Voduc, Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer, JNCI Journal of the National Cancer Institute, vol.101, issue.10, pp.736-750, 2009.
DOI : 10.1093/jnci/djp082

R. Tashima, Evaluation of an optimal cut-off point for the Ki-67 index as a prognostic factor in primary breast cancer, 2012.

A. Goldhirsch, E. Winer, A. Coates, R. Gelber, M. Piccart-gebhart et al., Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Annals of Oncology, vol.24, issue.9, pp.2206-2223, 2013.
DOI : 10.1093/annonc/mdt303

D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich et al., Human breast cancer: correlation of relapse and survival with amplification of the

D. Slamon, L. , B. Shak, S. Fuchs, H. Paton et al., Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, New England Journal of Medicine, vol.344, issue.11, pp.783-792, 2001.
DOI : 10.1056/NEJM200103153441101

S. Paik, G. Tang, and S. Shak, Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor???Positive Breast Cancer, Journal of Clinical Oncology, vol.24, issue.23, pp.3726-3734, 2006.
DOI : 10.1200/JCO.2005.04.7985

B. Fisher, J. Costantino, C. Redmond, R. Poisson, D. Bowman et al., A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor???Positive Tumors, New England Journal of Medicine, vol.320, issue.8, pp.479-84, 1989.
DOI : 10.1056/NEJM198902233200802

S. Paik, S. Shak, G. Tang, C. Kim, J. Baker et al., A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer, New England Journal of Medicine, vol.351, issue.27, pp.2817-2843, 2004.
DOI : 10.1056/NEJMoa041588

. Van-'t, L. Veer, H. Dai, M. Van-de-vijver, Y. He et al., Gene expression profiling predicts clinical outcome of breast cancer, Nature, vol.415, issue.6871, pp.530-536, 2002.

M. Van-de-vijver, Y. He, . Van-'t, L. Veer, H. Dai et al., A Gene-Expression Signature as a Predictor of Survival in Breast Cancer, New England Journal of Medicine, vol.347, issue.25, pp.1999-2009, 2002.
DOI : 10.1056/NEJMoa021967

M. Buyse, S. Loi, L. Van-'t-veer, G. Viale, M. Delorenzi et al., Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer, JNCI Journal of the National Cancer Institute, vol.98, issue.17
DOI : 10.1093/jnci/djj329

C. Sotiriou, S. Wirapati, and . Loi, Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis, JNCI Journal of the National Cancer Institute, vol.98, issue.4, pp.262-272, 2006.
DOI : 10.1093/jnci/djj052

M. Sola, J. A. Alberro, M. Fraile, P. Santesteban, M. Ramos et al., Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048, 2000.

K. Dowlatshahi, M. Fan, H. Snider, and F. Habib, Lymph node micrometastases from breast carcinoma, Cancer, vol.221, issue.7, pp.1188-97, 1997.
DOI : 10.1002/(SICI)1097-0142(19971001)80:7<1188::AID-CNCR2>3.0.CO;2-H

M. Hery, T. Delozier, A. Ramaioli, J. Julien, B. De-lafontan et al., Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse?, The Breast, vol.11, issue.5, pp.442-450, 2002.
DOI : 10.1054/brst.2002.0462

K. Albain, W. Barlow, O. Malley, and F. , Concurrent versus sequential chemohormonal therapy versus tamoxifen alone for postmenopausal, node?positive, ER and/or PgR?positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (S8814), Breast Cancer Res Treat, vol.90, p.95, 2005.

M. Dowsett, . Goldhirsch, . Hayes, . Hj-senn, and G. Wood, International Web-based consultation on priorities for translational breast cancer research, Breast Cancer Research, vol.59, issue.6, p.81, 2007.
DOI : 10.1136/jcp.2005.033043

T. Sorlie, . Tibshirani, and . Parker, Repeated observation of breast tumor subtypes in independent gene expression data sets, Proceedings of the National Academy of Sciences, vol.100, issue.14, pp.8418-8423, 2003.
DOI : 10.1073/pnas.0932692100

J. Hornberger and R. Chien, Meta-analysis of the decision impact of the 21-gene breast cancer recurrence score in clinical practice [abstract] Cancer Res, p.210, 2010.

G. Lyman, L. Cosler, and N. Kuderer, Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer, Cancer, vol.7, issue.6, pp.1011-1018, 2007.
DOI : 10.1002/cncr.22506

N. Lamond, C. Skedgel, D. Rayson, L. Lethbridge, and T. Younis, Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer, Breast Cancer Research and Treatment, vol.4, issue.6, pp.10549-10561
DOI : 10.1007/s10549-012-1989-5

B. Weigelt and R. Mackay, Breast cancer molecular profiling with single sample predictors: a retrospective analysis, The Lancet Oncology, vol.11, issue.4, pp.339-349, 2010.
DOI : 10.1016/S1470-2045(10)70008-5